Showing 1801-1810 of 2150 results for "".
- EMA’s CHMP Issues Negative Opinion of Syfovre for GA; Apellis to Seek Re-Examinationhttps://modernod.com/news/emas-chmp-issues-negative-opinion-for-syfovre-for-ga-apellis-to-seek-re-examination/2482336/The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the marketing authorization application (MAA) of Apellis’s intravitreal pegcetacoplan for the treatment of geographic atrophy (GA). “Although th
- Zeiss Announces OCT Enhancements to Cirrus 6000https://modernod.com/news/zeiss-announces-oct-enhancements-to-cirrus-6000/2482299/Zeiss Medical Technology announced enhancements to the Cirrus 6000 designed to allow for a more efficient and data-driven workflow for ophthalmologists. The device is supported by the largest OCT reference database in the US market, according to Zeiss, as well a
- Quantel Medical Launches POCKET III Handheld Pachymeterhttps://modernod.com/news/quantel-medical-launches-pocket-iii-handheld-pachymeter/2482298/Quantel Medical, a division of Lumibird Medical, announced the launch of the POCKET III handheld pachymeter. With its compact design, Quantel says the POCKET III is the lightest connected handheld pachymeter on the market weighing just 60 grams. It offers a precise a
- Outlook Therapeutics Receives European Authorization for Lytenava for the Treatment of Wet AMDhttps://modernod.com/news/outlook-therapeutics-receives-european-authorization-for-lytenava-bevacizumab-gamma-for-the-treatment-of-wet-amd/2482296/Outlook Therapeutics has received European Commission Marketing Authorization for Lytenava (bevacizumab gamma), an ophthalmic formulation of bevacizumab for the treatment of wet AMD. Lytenava is the first and only authorized ophthalmic formulation of bevacizumab for use in tre
- Regeneron Backs $500 Million Venture Capital Fund for Biotechnology Innovationhttps://modernod.com/news/regeneron-backs-500-million-venture-capital-fund-for-biotechnology-innovation/2482234/Regeneron Ventures announces its formation as a venture capital fund focused on promising biopharmaceutical, health care and health technology companies. The fund’s general partner will be independently managed by former Regeneron executives Jay S. Markowitz, MD, and Michael Aberman, M
- Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Drugshttps://modernod.com/news/harrow-licenses-canadian-rights-to-apotex-for-five-branded-ophthalmic-drugs/2482117/Harrow and Canadian pharma company Apotex jointly announced an exclusive out-licensing agreement under which Apotex will market and distribute Verkazia and over-the-counter (OTC) Cationorm PLUS in the Canadian market, and concurrently, pursue market approval in Canada for Ve
- Apellis Receives Negative Opinion for Pegcetacoplan for GA in the EU; Plans to Seek Re-Examination of Applicationhttps://modernod.com/news/apellis-receives-negative-opinion-for-pegcetacoplan-for-ga-in-the-eu-plans-to-seek-re-examination-of-application/2482083/Apellis Pharmaceuticals announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a negative opinion on the marketing authorization application (MAA) of intravitreal pegcetacoplan for the treatment of geographic atrophy (GA) secondary to
- Zeiss’ Visumax 800 With Smile Pro Software Approved by FDAhttps://modernod.com/news/zeiss-visumax-800-with-smile-pro-software-approved-by-fda/2482056/Zeiss Medical Technology announced that the FDA has approved the Visumax 800 With Smile Pro software for surgically treating nearsightedness, with or without astigmatism. This latest generation of femtosecond lasers from Zeiss enters the United States market as the technology is being broadly ado
- Eylea 8 mg Approved in EUhttps://modernod.com/news/eylea-8-mg-approved-in-eu/2482046/The European Commission has granted marketing authorization in the European Union (EU) for new Eylea 8 mg (aflibercept 8 mg, 114.3 mg/ml solution for injection) for the treatment of wet age-related macular degeneration (AMD) and visual impairment due to diabetic macular edema (DME).
- Visiox Pharmaceuticals to be Listed on Nasdaq Through Combination with PowerUp Acquisitionhttps://modernod.com/news/visiox-pharmaceuticals-to-be-listed-on-nasdaq-through-combination-with-powerup-acquisition/2482029/Visiox Pharmaceuticals and PowerUp Acquisition Corp. announced the execution of a definitive agreement for a business combination that would result in Visiox becoming a publicly traded company on the Nasdaq Capital Market. The business combination is expected to close in the first quarter of